Steminent Biotherapeutics Inc. (TPEX: 7729)
Health Care · Biotechnology · TW
NT$79.10
+2.33% today · +91.1% 1Y
Steminent Biotherapeutics Inc. (TPEX: 7729) operates in the Biotechnology industry within the Health Care sector. The company is valued at $164.73M and employs 55 people.
Over the last twelve months the share price has gained 91.1%, trading between 34.00 and 95.60.
Tweenvest scores Steminent Biotherapeutics Inc. across four factors: quality 28/100. Its strongest factor is quality.
7729 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $164.73M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.95
- Dividend yield
- —
- Beta (5Y)
- 0.15
- 52-week high
- NT$95.60
- 52-week low
- NT$34.00
- Avg volume (3M)
- —
- Shares outstanding
- 66.63M
- Employees
- 55
- Next earnings
- —
About Steminent Biotherapeutics Inc.
Steminent Biotherapeutics Inc. is a biopharmaceutical company dedicated to pioneering novel cellular therapeutics, with a primary focus on the research and development of innovative stem cell drugs. Their flagship product is Stemchymal, which is recognized for its significant therapeutic benefits and broad range of potential applications. The firm was established on December 18, 2007, and operates from its headquarters in Taipei, Taiwan.
- ISIN
- TW0007729006
- Founded
- 2009
- Listed since
- Mar 11, 2024
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.16 | -0.14% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $445.53 | +0.38% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €873.60 | +1.09% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $141.30 | +1.74% |
Figures last refreshed Aug 18, 2026.